Townsend Richard Nolan 4

What Happened

• Richard Nolan, Chief Executive Officer of Lexeo Therapeutics (LXEO), acquired 2,623 shares of common stock on March 13, 2026. The shares were purchased at $2.64 per share for a total of approximately $6,935. The transaction is reported as an Award/Grant/Acquisition (code A) tied to the company's employee plan.

Key Details

• Transaction date: 2026-03-13; Form 4 filed: 2026-03-17 (filed within standard SEC timing for Form 4).
• Price per share: $2.64; total value: ~$6,935.
• Transaction type: Acquisition under the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan (ESPP).
• Footnotes: F1 — transaction reported voluntarily and exempt under Rule 16b-3(c) and 16b-3(d) as a benefit-plan acquisition. F2 — filing notes inclusion of 261,349 Restricted Stock Units (RSUs).
• Shares owned after transaction: Not explicitly stated in the provided data; filing footnote references 261,349 RSUs as part of reported holdings.

Context

• This was an ESPP purchase — a routine employee benefit-plan acquisition that is typically exempt from short-swing profit recovery under Rule 16b-3. Small-dollar insider purchases like this add direct ownership but do not, by themselves, indicate broader company direction.